Breaking News

Diet Pill May Also Help Reduce Liver Damage

Acomplia (rimonabant) works by blocking the CB1 receptor in the brain and fat tissue. cannabinoids convert to CB1 receptors and send signals that encourage people to eat more. These receptors tend to be more active in overweight people.

In clinical trials. Acomplia (rimonabant) has been shown to help people with weight loss when taken regularly as a slimming aid. There is also evidence that it also reduces the amount of auditory fat in the abdominal cavity associated with heart disease and diabetes.

Recent research in Sanofi-Aventis rimonabant developers, suggests another possible health benefit for Acomplia (rimonabant) controversial diet pills users. Apparently it can also reduce liver damage associated with obesity, which in turn can lead to cirrhosis.

The study, led by Mohammed Bensaid of Sanofi-Aventis, was performed on obese male rats given oral rimonabant for 8 weeks. Test results show that treatment reduces liver enlargement, kills hepatic steatosis, and reduces blood markers of enzymes that suggest liver damage. Another benefit is reduced hepatic levels of TNFa, a pro-inflammatory protein that is thought to be responsible for inducing insulin resistance in the liver.

Animal studies revealed little or no improvement in control rats given the same diet but did not receive rimonabant, indicating that the benefits were associated with dietary pills.

Researchers believe that multiple protective effects of Acomplia (rimonabant) may be associated with a reduction in pro-inflammatory cytokines, and an increase in anti-inflammatory and protective cytokines. This indicates the potential for medical applications for Acomplia (rimonabant) in the treatment of liver diseases related to obesity and metabolic syndrome. "



------------------

No comments